# Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

> **NCT04630522** · PHASE1 · COMPLETED · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 295 (actual)

## Conditions studied

- Bone Metastases From Solid Tumors

## Interventions

- **DRUG:** Drug: JMT103- 120 mg SC Q4W
- **DRUG:** Drug: JMT103- 120 mg SC Q8W
- **DRUG:** Drug: JMT103- 180 mg SC Q8W
- **DIETARY_SUPPLEMENT:** Dietary Supplement: Calcium Dietary Supplement: Vitamin D

## Key facts

- **NCT ID:** NCT04630522
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-31
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630522, "Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04630522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*